Sientra to Report First Quarter 2020 Financial Results on May 11, 2020
Sientra, Inc. (NASDAQ: SIEN) announced it will release its financial results for Q1 2020 after market close on May 11, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sientra, Inc. (NASDAQ: SIEN) announced it will release its financial results for Q1 2020 after market close on May 11, 2020. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss these results. Domestic callers can dial 844-464-3933, while international participants can reach 765-507-2612 using conference ID 3594402. The call will be webcast live on Sientra's Investor Relations website and archived for later access. Sientra focuses on medical aesthetics, offering advanced breast products and the miraDry system for sweat and odor treatment.
Details
News Market Reaction – SIEN
The recorded move for SIEN in the trading session of this news was +2.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA BARBARA, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that it will release financial results for the first quarter of 2020 after the close of trading on Monday, May 11, 2020. Sientra will host a conference call to discuss financial results the same day at 5:00 p.m. Eastern Time.
The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 3594402.
A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its OPUS® breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprises its miraDry® system, which is approved for sale in over 40 international markets, and is the only non-surgical FDA-cleared device for the permanent reduction of underarm sweat, odor and hair of all colors.
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.
(*) Data on file
Contact
Investor Relations
805-679-8885
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.